Frazier Life Sciences XI, L.P. bought $10.0M of ATTO
owner at Attovia Therapeutics, Inc.. 588,235 shares at an average of $17.00, traded Aug 6, 2026, filed Aug 6, 2026.
Score components
- +12Role10% owner
- +25Trade size$10.0M at market
- +3Relative to holdingsHoldings up 11%
- 0Price contextNo price history yet
- +15Cluster6 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-26-000838, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | CConversion Common Stock | +1,749,192 | - | - | 1,824,541 | Aug 6, 2026 |
| Aug 6, 2026 | CConversion Common Stock | +1,590,175 | - | - | 3,414,716 | Aug 6, 2026 |
| Aug 6, 2026 | CConversion Common Stock | +1,189,940 | - | - | 4,604,656 | Aug 6, 2026 |
| Aug 6, 2026 | CConversion Common Stock | +961,322 | - | - | 5,565,978 | Aug 6, 2026 |
| Aug 6, 2026 | POpen-market purchase Common Stock | +588,235 | $17.00 | $10.0M | 6,154,213 | Aug 6, 2026 |
| Aug 6, 2026 | CConversion Series A-1 Preferred Stockderivative | -16,250,000 | $0.00 | $0 | 0 | Aug 6, 2026 |
| Aug 6, 2026 | CConversion Series A-2 Preferred Stockderivative | -14,772,727 | $0.00 | $0 | 0 | Aug 6, 2026 |
| Aug 6, 2026 | CConversion Series B Preferred Stockderivative | -11,054,544 | $0.00 | $0 | 0 | Aug 6, 2026 |
| Aug 6, 2026 | CConversion Series C Preferred Stockderivative | -8,930,685 | $0.00 | $0 | 0 | Aug 6, 2026 |
Related signals
Other insiders at Attovia Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 56Moderate | Attovia Therapeutics, Inc. | Goldman Sachs Group Inc other | $10M 585,000 shares | - | |
| 61Notable | Attovia Therapeutics, Inc. | Goldman Sachs Group Inc other | $2.3M 105,807 shares | -124% | |
| 63Notable | Attovia Therapeutics, Inc. | Colin Walsh director | $10M 585,000 shares | - | |
| 68Notable | Attovia Therapeutics, Inc. | Colin Walsh director | $2.3M 105,807 shares | -124% | |
| 56Moderate | Attovia Therapeutics, Inc. | Goldman Sachs Group Inc other | $10M 585,000 shares | - | |
| 61Notable | Attovia Therapeutics, Inc. | Goldman Sachs Group Inc other | $2.3M 105,807 shares | -124% | |
| 63Notable | Attovia Therapeutics, Inc. | Colin Walsh director | $10M 585,000 shares | - | |
| 68Notable | Attovia Therapeutics, Inc. | Colin Walsh director | $2.3M 105,807 shares | -124% | |
| 50Moderate | Attovia Therapeutics, Inc. | venBio Global Strategic Fund IV, L.P. owner | $6.5M 382,352 shares | +10% | |
| 52Moderate | Attovia Therapeutics, Inc. | Redmile Group, LLC owner | $10M 600,000 shares | +77% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.